title: Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition.
abstract: In this issue of Cancer Cell, Mohammad et al. describe LSD1, a histone demethylase, as a therapeutic target in SCLC with a unique epigenetic signature to predict drug sensitivity. Inhibition of LSD1 reduces cell proliferation and stem cell maintenance while promoting cell differentiation and reducing tumor growth in preclinical models.
authors.affiliation: Department of Thoracic and Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: C Allison
authors.initials: CA
authors.lastname: Stewart
authors.affiliation: Department of Thoracic and Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: lbyers@mdanderson.org.
authors.forename: Lauren Averett
authors.initials: LA
authors.lastname: Byers
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001565:Benzoates / Q000008:administration & dosage*; D003521:Cyclopropanes / Q000008:administration & dosage*; D019175:DNA Methylation / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D056466:Histone Demethylases / Q000037:antagonists & inhibitors*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D001565:Benzoates; D003521:Cyclopropanes; D004791:Enzyme Inhibitors; D056466:Histone Demethylases